Tech Company Financing Transactions
TenSixteen Bio Funding Round
Foresite Capital and GV participated in a $40 million funding round for TenSixteen Bio. This venture round was announced on 2/3/2022.
Transaction Overview
Company Name
Announced On
2/3/2022
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Foresite Capital (Vikram Bajaj)
GV (Krishna Yeshwant)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Overview
TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Chao
Browse more venture capital transactions:
Prev: 2/3/2022: Distalmotion venture capital transaction
Next: 2/3/2022: Cialfo venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs